CYTK vs ICLR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CYTK shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 5/9). Mixed signals with both opportunities and risks present.
ICLR presents a stark divergence between fundamental stability and growth performance. While the Piotroski F-Score of 7/9 indicates strong financial health and the stock trades below its book value (P/B 0.87) and Graham Number ($142.86), the growth profile has collapsed with YoY earnings plummeting -98.7%. The company is fundamentally sound from a balance sheet perspective, but the extreme PEG ratio (17.68) and bearish technical trend suggest a value trap unless the recent earnings crash is a one-time anomaly.
Compare Another Pair
Related Comparisons
CYTK vs ICLR: Head-to-Head Comparison
This page compares Cytokinetics, Incorporated (CYTK) and ICON Public Limited Company (ICLR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.